Biotech venture capital investments remain on pace for a record year after racking up another $2 billion in the third quarter, but some current shakiness in the public markets could change the outlook for early-stage drug developers looking to fill their coffers in the future.
With crossover investors still crowding into the biotech field to help launch a wave of new IPOs, the industry recorded $1.7 billion in new venture funds in the first quarter, according to The MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association based on data from Thomson Reuters.
The venture capital invested in med tech startups dipped below $500 million during the first quarter--for the first time since the fourth quarter of 2013, according to the MoneyTree Report from PricewaterhouseCoopers and the National Venture Capital Association based on data provided by Thomson Reuters.
Med tech venture investing may lag biotech by more than half, but it's coming on strong. As venture-backed exits pick up, a real devotion to breakthrough innovation seems to be whetting investor appetites. A total of $2.7 billion was invested by VCs last year in medical devices and diagnostics, with $748 million of that total coming during the fourth quarter.
Last quarter biotech attracted a whopping $1.8 billion in new venture cash, the biggest quarter since 2005.
U.S. biotech companies attracted a bountiful $1.3 billion venture haul in the fourth quarter of 2013, pushing the total for the year to $4.53 billion--well ahead of 2012's mark of $4.19 billion and a hopeful sign of continued activity headed into 2014.
In 2013, VCs spent $2.1 billion on 308 medical device investment deals, representing a 17% plunge in dollars and 4% drop in deals compared to the year before, according to the latest MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association, based on Thomson Reuters data.
There were a few misfires on the biotech IPO front in the fourth quarter of 2013, but the National Venture Capital Association says it tallied 6 newly minted public drug developers in the period, winding up a big year.
In this list of the top 10 med tech VC deals for Q3, one thing is painfully clear: Early-stage innovators are out of the picture. The winning companies are relatively far along, looking to expand...
An interesting thing happened on the way through 2013: Biotechnology venture investing began to see a healthy rebound in the second quarter, but medical device investing stayed essentially flat compared to the first three months of the year. Check out the report >>